-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 D1kGnuv3wz3M0o4S1+MWI+9gdRg1wFVE6zDSVUyBIz0gbzy3KULrTGuft/2FAng5
 gOmIINtf2dQNKeWq+xD5fA==

<SEC-DOCUMENT>0001104659-10-055722.txt : 20101104
<SEC-HEADER>0001104659-10-055722.hdr.sgml : 20101104
<ACCEPTANCE-DATETIME>20101104060404
ACCESSION NUMBER:		0001104659-10-055722
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20101103
FILED AS OF DATE:		20101104
DATE AS OF CHANGE:		20101104

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVARTIS AG
		CENTRAL INDEX KEY:			0001114448
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-15024
		FILM NUMBER:		101163061

	BUSINESS ADDRESS:	
		STREET 1:		LICHSTRASSE 35
		CITY:			BASEL SWITZERLAND
		STATE:			V8
		ZIP:			CH 4056

	MAIL ADDRESS:	
		STREET 1:		LICHSTRASSE 35
		CITY:			BASEL SWITZERLAND
		ZIP:			CH 4056
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>a10-20551_26k.htm
<DESCRIPTION>6-K
<TEXT>

<html>

<head>






</head>

<body lang="EN-US">

<div style="font-family:Times New Roman;">

<div style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 3.0pt;padding:1.0pt 0in 1.0pt 0in;">

<p style="border:none;margin:0in 0in .0001pt;padding:0in;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>

</div>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Washington, D.C. 20549</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">FORM&nbsp;6-K</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">REPORT
OF FOREIGN PRIVATE ISSUER</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">PURSUANT
TO RULE 13a-16 or 15d-16 OF</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">THE
SECURITIES EXCHANGE ACT OF 1934</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Report on Form&nbsp;6-K dated November&nbsp;3, 2010</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(Commission File No.&nbsp;1-15024)</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<div align="center" style="margin:0in 0in .0001pt;text-align:center;"><hr size="1" width="25%" noshade color="black" align="center"></div>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">Novartis AG</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Name of Registrant)</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Lichtstrasse 35</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">4056 Basel</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Switzerland</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Address of Principal Executive Offices)</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<div align="center" style="margin:0in 0in .0001pt;text-align:center;"><hr size="1" width="25%" noshade color="black" align="center"></div>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Indicate
by check mark whether the registrant files or will file annual reports under
cover of Form&nbsp;20-F or Form&nbsp;40-F:</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<div align="center">

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.5%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Form&nbsp;20-F: </font></b><font size="2" face="Wingdings" style="font-size:10.0pt;">x</font></p>
  </td>
  <td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.5%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Form&nbsp;40-F:
  </font><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font></p>
  </td>
 </tr>
</table>

</div>

<p style="margin:0in 0in .0001pt;text-align:justify;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Indicate
by check mark if the registrant is submitting the Form&nbsp;6-K in paper as
permitted by Regulation S-T Rule&nbsp;101(b)(1):</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<div align="center">

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.5%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Yes: </font><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font></p>
  </td>
  <td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
  <td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.5%;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">No</font></b><font size="2" style="font-size:10.0pt;">: </font><font size="2" face="Wingdings" style="font-size:10.0pt;">x</font></p>
  </td>
 </tr>
</table>

</div>

<p style="margin:0in 0in .0001pt;text-align:justify;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Indicate
by check mark if the registrant is submitting the Form&nbsp;6-K in paper as
permitted by Regulation S-T Rule&nbsp;101(b)(7):</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<div align="center">

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.5%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Yes: </font><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font></p>
  </td>
  <td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
  <td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.5%;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">No</font></b><font size="2" style="font-size:10.0pt;">: </font><font size="2" face="Wingdings" style="font-size:10.0pt;">x</font></p>
  </td>
 </tr>
</table>

</div>

<p style="margin:0in 0in .0001pt;text-align:justify;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Indicate
by check mark whether the registrant by furnishing the information contained in
this form is also thereby furnishing the information to the Commission pursuant
to Rule&nbsp;12g3-2(b)&nbsp;under the Securities Exchange Act of 1934.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<div align="center">

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.5%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Yes: </font><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font></p>
  </td>
  <td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
  <td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.5%;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">No</font></b><font size="2" style="font-size:10.0pt;">: </font><font size="2" face="Wingdings" style="font-size:10.0pt;">x</font></p>
  </td>
 </tr>
</table>

</div>

<p style="margin:0in 0in .0001pt;text-align:justify;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<div style="border-bottom:solid windowtext 3.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:1.0pt 0in 1.0pt 0in;">

<p style="border:none;margin:0in 0in .0001pt;padding:0in;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>

</div>

<p style="margin:0in 0in .0001pt;text-align:justify;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\105953\10-20551-2\task4342131\20551-2-ba.htm',USER='105953',CD='Nov  4 08:15 2010' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.34%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman"><img width="192" height="41" src="g205512bai001.jpg"></font></p>
  </td>
  <td width="39%" valign="bottom" style="padding:0in 0in 0in 0in;width:39.16%;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
  <td width="27%" valign="top" style="padding:0in 0in 0in 0in;width:27.5%;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Novartis International AG<br>
  </font></b><font size="2" style="font-size:10.0pt;">Novartis Global
  Communications<br>
  </font><font size="2" style="font-size:10.0pt;">CH-4002 Basel<br>
  Switzerland<br>
  http://www.novartis.com</font></p>
  </td>
 </tr>
</table>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">- Investor Relations Release -</font></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Study in NEJM shows Novartis drug
Afinitor</font></b><b><font size="1" style="font-size:6.5pt;font-weight:bold;position:relative;top:-3.0pt;">&#174;</font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">&#160;reduces size of SEGAs,
</font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">benign brain tumors associated with tuberous sclerosis</font></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><i><font size="2" style="font-size:10.0pt;font-style:italic;">Subependymal giant cell astrocytoma (SEGA) is a benign brain
tumor found in children and adults with tuberous sclerosis (TS) that can cause
severe brain swelling(1)</font></i></p>

<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><i><font size="2" style="font-size:10.0pt;font-style:italic;">These data previously reported at ASCO show nearly one-third
of the 28 patients studied had a reduction of 50% or greater in the size of
their largest SEGA(2)</font></i></p>

<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><i><font size="2" style="font-size:10.0pt;font-style:italic;">Additional study findings showed treatment with everolimus
resulted in a clinically relevant reduction in overall frequency of seizures,
which are associated with TS(2)</font></i></p>

<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><i><font size="2" style="font-size:10.0pt;font-style:italic;">Afinitor approved in US for patients with SEGA associated
with TS who require therapeutic intervention but are not candidates for
curative surgical resection(3)</font></i></p>

<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Basel, November&nbsp;3, 2010</font></b><font size="2" style="font-size:10.0pt;">  <b>&#151;</b></font><font size="2" style="font-size:10.0pt;">  </font><i><font size="2" style="font-size:10.0pt;font-style:italic;">The</font></i><font size="2" style="font-size:10.0pt;">  <i>New England Journal of Medicine </i>(NEJM) today published a
study that<i>  </i>found patients taking Afinitor</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">&#174;</font><font size="2" style="font-size:10.0pt;">&#160;(everolimus) tablets experienced a decrease in
the size of their subependymal giant cell astrocytoma (SEGA), a benign brain
tumor associated with tuberous sclerosis (TS)(1),(2). This study, which was
previously presented at the 46</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">th</font><font size="2" style="font-size:10.0pt;">&#160;American
Society of Clinical Oncology annual meeting, is the first prospective clinical
trial of a drug to show treatment benefit in these patients.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Tuberous sclerosis is a
genetic disorder affecting approximately 25,000 to 40,000 people in the US. Tuberous
sclerosis may cause benign tumors to form in vital organs, including the brain,
where they can cause seizure and developmental delay, as well as the kidney,
heart, eyes, lungs and skin(4). SEGAs, benign brain tumors, occur in up to 20%
of patients with TS and primarily affect children and adolescents(1),(5),(6).
SEGAs may pose a significant medical risk, including the potential for swelling
in the brain, or hydrocephalus(1)</font><font size="2" style="font-size:10.0pt;">.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">According
to data published in NEJM from </font><font size="2" style="font-size:10.0pt;">this Phase I/II study of 28
patients conducted by Cincinnati Children&#146;s Hospital Medical Center, treatment
with everolimus was associated with a significant reduction in primary SEGA
volume at six months relative to baseline on independent central review
(p&lt;0.001). Seventy-five percent of patients (21 of 28) experienced a
reduction of 30% or greater in the size of their largest SEGA and 32% (9 of 28)
experienced a reduction of 50% or greater at six months relative to
baseline(2).</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The published study findings
also showed that everolimus therapy was associated with a clinically relevant
reduction from baseline to six months in overall frequency of seizures per 24
hour video electroencephalograms (EEG) (n=16; median change -1 seizure,
p=0.022). Additionally, no patients</font><font size="2" style="font-size:10.0pt;">  </font><font size="2" style="font-size:10.0pt;">required surgery or developed a new SEGA while receiving everolimus(2)</font><font size="2" style="font-size:10.0pt;">.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Everolimus was recently
approved in the US under the FDA&#146;s accelerated approval program as Afinitor for
patients with SEGA associated with TS who require therapeutic intervention but
are </font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<div style="margin:0in 0in .0001pt;text-autospace:none;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\105953\10-20551-2\task4342131\20551-2-ba.htm',USER='105953',CD='Nov  4 08:15 2010' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">not candidates for curative
surgical resection. The effectiveness of Afinitor is based on an analysis of
change in SEGA volume</font><font size="2" style="font-size:10.0pt;">(3)</font><font size="2" style="font-size:10.0pt;">. A Phase III study is underway that compares everolimus to placebo to
explore the clinical benefits of Afinitor for the treatment of patients with
SEGA associated with TS</font><font size="2" style="font-size:10.0pt;">(7)</font><font size="2" style="font-size:10.0pt;">.</font></p>

<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The most common adverse
reactions observed (incidence <u>&gt;</u>30%) in this trial were mouth sores,
upper respiratory tract infections, sinusitis, middle ear infections and
fever(2).</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;This is the first clinical trial to show that a drug
has the potential to provide</font><font size="2" style="font-size:10.0pt;"> patients with growing SEGAs, many of whom are children, another
treatment option besides brain surgery</font><font size="2" style="font-size:10.0pt;">,&#148;
said David Franz, MD, Director, Tuberous Sclerosis Clinic at Cincinnati
Children&#146;s Hospital Medical Center and principal investigator of the study. &#147;In
addition to decreasing the size of the brain tumors, everolimus was associated
with a significant reduction in the frequency of seizures, which occur in 90%
of affected individuals.&#148;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">About the study published in NEJM</font></b></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In this Phase I/II study, 28
patients aged three years and above (median age=11, range 3-34) with evidence
of SEGA growth initially received everolimus orally at a dose of 3 mg/m(2)&nbsp;once-daily
or on an alternate day regimen. Doses were subsequently adjusted subject to
tolerability to attain a trough concentration of 5-15 ng/mL(2).</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The study met its primary
efficacy endpoint of change in primary SEGA lesion volume from baseline to six
months (or at the last available assessment if a patient discontinued treatment
prior to month six [one patient discontinued the trial before six months]). Everolimus was associated with a
statistically significant reduction in primary SEGA volume at six months
relative to baseline on independent
central review (p&lt;0.001). As of December&nbsp;9, 2009, the median
duration of treatment was 21.5 months(2).</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Study findings also showed
that everolimus was associated with a clinically relevant reduction from
baseline to six months in overall frequency of seizures per 24 hour EEG (n=16;
median change -1.0 seizure, p=0.022). Of 16 patients with seizures at the start
of the study for whom EEGs were available, nine experienced decreases in
seizure frequency, six reported no change and one experienced an increase at
six months(2).</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The reliability of the
frequency of adverse reactions and laboratory abnormalities reported in this
trial is limited because of the small number of patients. The most common
adverse reactions reported (incidence <u>&gt;</u>30%) in this trial were mouth
sores, upper respiratory tract infections, sinusitis, middle ear infections and
fever(2).</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">All data reported in this
study published in NEJM<i>  </i>are based on
the cut-off date of December&nbsp;9, 2009(2).</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">About the EXIST-1 Phase III trial</font></b></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">EXIST-1, a Phase III
randomized, placebo-controlled trial aimed at evaluating the results of the
Phase I/II study, is examining everolimus treatment in patients with SEGAs
associated with TS. Endpoints include SEGA response rate, seizure rate, skin
lesion response rate and safety. The trial has completed accrual and patients
continue to be followed(7).</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The trial involves patients
in 10 countries, including Australia, Belgium, Canada, Germany,&nbsp;Italy, the
Netherlands, Poland, Russia, the UK and the US(7).</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">About Afinitor (everolimus)</font></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Afinitor</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">&#174;</font><font size="2" style="font-size:10.0pt;">&#160;(everolimus) tablets is approved in the US to
treat patients with SEGA associated with tuberous sclerosis who require
therapeutic intervention but are not candidates for curative </font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\105953\10-20551-2\task4342131\20551-2-ba.htm',USER='105953',CD='Nov  4 08:15 2010' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">surgical
resection. The effectiveness of Afinitor is based on an analysis of change in
SEGA volume. Improvement in disease-related symptoms or increase in survival
has not been shown.</font></p>

<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Novartis
has submitted marketing applications for everolimus to the European Medicines
Agency (EMA) and the Swiss Agency for Therapeutic Products (Swissmedic), and
additional regulatory submissions are underway worldwide. If approved in the
European Union (EU) for this indication, everolimus will be made available
under the trade name Votubia</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">&#174;</font><font size="2" style="font-size:10.0pt;">.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">There
is no guarantee that everolimus will become commercially available for SEGA
anywhere else in the world. As an investigational compound, the safety and
efficacy profile of everolimus has not yet been established outside the US in
patients with SEGA associated with TS.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Afinitor
is approved in the European Union (EU) for the treatment of patients with
advanced renal cell carcinoma (RCC) whose disease has progressed on or after
treatment with vascular endothelial growth factor (VEGF)-targeted therapy and
also in the US for the treatment of patients with advanced RCC after failure of
treatment with sunitinib or sorafenib.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In
the EU, everolimus is available in different dosage strengths under the trade
name Certican</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">&#174;</font><font size="2" style="font-size:10.0pt;">&#160;for the prevention of organ rejection in heart
and kidney transplant recipients. In the US, everolimus is available in
different dosage strengths under the trade name Zortress</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">&#174;</font><font size="2" style="font-size:10.0pt;">&#160;for the prophylaxis of organ rejection in
adult patients at low-moderate immunologic risk receiving a kidney transplant.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Not
all indications are available in every country.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Important Safety Information about Afinitor (everolimus)
tablets</font></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Afinitor
is contraindicated in patients with hypersensitivity to everolimus, to other
rapamycin derivatives or to any of the excipients.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cases
of non-infectious pneumonitis have been described; some of these have been
severe and occasionally fatal. Management of pneumonitis may require dose
adjustment and/or interruption, or discontinuation of treatment and/or addition
of corticosteroid therapy.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Afinitor
is immunosuppressive. Localized and systemic bacterial, fungal, viral or
protozoal infections (e.g., pneumonia, aspergillosis, candidiasis, hepatitis B
reactivation) have been described; some of these have been severe and
occasionally fatal. Pre-existing infections should be treated prior to starting
treatment. Patients and physicians should be vigilant for symptoms and signs of
infection; in case of emergent infections, appropriate treatment should be
promptly instituted and interruption or discontinuation of Afinitor should be
considered. Patients with systemic invasive fungal infections should not
receive Afinitor.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Mouth
ulcers, stomatitis and oral mucositis have been seen in patients treated with
Afinitor. Monitoring of renal function, blood glucose and complete blood counts
is recommended prior to initiation and periodically during treatment.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Afinitor
is not recommended in patients with severe hepatic impairment. Use of live
vaccines should be avoided. Afinitor is not recommended during pregnancy or for
women of childbearing potential not using contraception. Afinitor may cause
fetal harm in pregnant women. Women taking Afinitor should not breast feed.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Avoid
concurrent treatment with strong CYP3A4 and PgP inhibitors and use caution with
moderate inhibitors. Avoid concurrent treatment with strong CYP3A4 or PgP
inducers.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In
advanced RCC, the most common adverse reactions (<u>&gt;</u>10%) include
stomatitis, rash, fatigue, asthenia, diarrhea, anorexia, nausea, mucosal
inflammation, vomiting, cough, infections, </font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\105953\10-20551-2\task4342131\20551-2-ba.htm',USER='105953',CD='Nov  4 08:15 2010' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">peripheral
edema, dry skin, epistaxis, pneumonitis, pruritus, and dyspnea. Common adverse
reactions (<u>&gt;</u>1 to &lt;10%) include headache, dysgeusia, dry mouth,
pyrexia, weight loss, hand-foot syndrome, abdominal pain, erythema, insomnia,
dyspepsia, dysphagia, hypertension, increased daytime urination, dehydration,
chest pain, hemoptysis and exacerbation of diabetes mellitus. Uncommon adverse
reactions (&lt;1%) include ageusia, congestive cardiac failure, new-onset
diabetes mellitus, impaired wound healing, grade 1 hemorrhage and hepatitis B
reactivation.</font></p>

<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In the SEGA study, the most
common adverse reactions (<u>&gt;</u>10%, all grades) irrespective of
relationship to the drug reported among the 28 patients with evidence of
established SEGA growth included: stomatitis or mouth sores, upper respiratory
tract infection, sinusitis, middle ear infection, fever, convulsion, acne-like
skin inflammation, diarrhea, cellulitis or acute infection of the deep tissues
of skin or muscle, vomiting, cough, body tinea or fungal infection, headache,
personality change, rash, skin infection, dry skin, gastroenteritis or
inflammation of the gastrointestinal tract, contact dermatitis, dizziness,
external ear infection, allergic rhinitis or inflammation of nasal passages,
gastric infection, nasal congestion, excoriation or skin abrasion, acne,
constipation, abdominal pain and pharyngitis or inflammation of the pharynx.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Grade three adverse
reactions irrespective of relationship to the study drug included convulsion,
infections (single cases of sinusitis, pneumonia, tooth infection and viral bronchitis)
and single cases of stomatitis, aspiration, cyclic neutropenia, sleep apnea
syndrome, vomiting, dizziness, white blood cell count decreased and neutrophil
count decreased. A grade four convulsion was reported.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Disclaimer</font></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The foregoing release contains
forward-looking statements that can be identified by terminology such as &#147;may,&#148;
&#147;potential,&#148; &#147;will,&#148; &#147;aimed at,&#148; or similar expressions, or by express or
implied discussions regarding potential new indications or labeling for
Afinitor or regarding potential future revenues from Afinitor. </font><font size="2" style="font-size:10.0pt;">You should not place undue reliance
on these statements.&#160; </font><font size="2" style="font-size:10.0pt;">Such forward-looking statements reflect the current
views of management regarding future events, and involve known and unknown
risks, uncertainties and other factors that may cause actual results with
Afinitor to be materially different from any future results, performance or
achievements expressed or implied by such statements. There can be no guarantee
that Afinitor will be submitted or approved for any additional indications or
labeling in any market. Nor can there be any guarantee that Afinitor will
achieve any particular levels of revenue in the future. In particular,
management&#146;s expectations regarding Afinitor could be affected by, among other
things, unexpected regulatory actions or delays or government regulation
generally; unexpected clinical trial results, including unexpected new clinical
data and unexpected additional analysis of existing clinical data; the company&#146;s
ability to obtain or maintain patent or other proprietary intellectual property
protection; competition in general; government, industry and general public
pricing pressures</font><font size="2" style="font-size:10.0pt;">;
the impact that the foregoing factors could have on the values attributed to
the Novartis Group&#146;s assets and liabilities as recorded in the Group&#146;s
consolidated balance sheet</font><font size="2" style="font-size:10.0pt;">, and
other risks and factors referred to in Novartis AG&#146;s current Form&nbsp;20-F on
file with the US Securities and Exchange Commission. Should one or more of
these risks or uncertainties materialize, or should underlying assumptions
prove incorrect, actual results may vary materially from those anticipated,
believed, estimated or expected. Novartis is providing the information in this
press release as of this date and does not undertake any obligation to update
any forward-looking statements contained in this press release as a result of
new information, future events or otherwise.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">About
Novartis</font></b></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Novartis provides healthcare
solutions that address the evolving needs of patients and societies. Focused solely
on healthcare, Novartis offers a diversified portfolio to best meet these
needs: innovative medicines, cost-saving generic pharmaceuticals, preventive
vaccines, diagnostic tools and consumer health products. Novartis is the only
company with leading positions in these areas. In 2009, the Group&#146;s continuing
operations achieved net sales of USD 44.3 billion, while approximately USD 7.5
billion was invested in R&amp;D activities throughout the Group. Headquartered </font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<div style="margin:0in 0in .0001pt;text-autospace:none;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\105953\10-20551-2\task4342131\20551-2-ba.htm',USER='105953',CD='Nov  4 08:15 2010' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">in Basel, Switzerland,
Novartis Group companies employ approximately 100.000 full-time-equivalent
associates and operate in more than 140 countries around the world. For more
information, </font><font size="2" style="font-size:10.0pt;">please
visit http://www.novartis.com</font><font size="2" style="font-size:10.0pt;">.</font></p>

<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Novartis is on Twitter. Sign
up to follow @Novartis at http://twitter.com/novartis.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<div style="margin:0in 0in .0001pt;text-autospace:none;"><hr size="1" width="25%" noshade color="black" align="left"></div>

<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">References</font></b></p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Adriaensen ME, et al.
Prevalence of subependymal giant cell tumors in patients with tuberous
sclerosis and a review of the literature. Eur J Neurol 2009; 16: 691-6.</font></p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(2)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Krueger D, et al. Everolimus
for Subependymal Giant-Cell Astrocytomas in Tuberous Sclerosis. N Engl J Med
2010; 363:1801-1811.</font></p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(3)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Novartis data on file.
http://www.pharma.us.novartis.com/product/pi/pdf/afinitor.pdf. Accessed October&nbsp;2010.</font></p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(4)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">National Institute of
Neurological Disorders and Stroke. Tuberous Sclerosis Fact Sheet. Available at
http://www.ninds.nih.gov/disorders/tuberous_sclerosis/detail_tuberous_sclerosis.htm.
Accessed October&nbsp;2010.</font></p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(5)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Medkour A, et al. Neonatal
Subependymal Giant Cell Astrocytoma. Pediatr Neurosurg 2002;36:271&#151;274.</font></p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(6)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Nabbout R, et al. Early
diagnosis of subependymal giant cell astrocytoma in children with tuberous
sclerosis. J Neurol Neurosurg Psychiatry 1999;66:370&#151;375.</font></p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(7)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">US
National Institutes of Health. Efficacy and Safety of RAD001 in Patients of All
Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous
Sclerosis Complex (TSC) (EXIST-1). Available at: </font><font size="2" style="font-size:10.0pt;">http://clinicaltrials.gov/ct2/show/NCT00789828?term=exist-1&amp;rank=1.
Accessed October&nbsp;2010.</font></p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"># # #</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Novartis Media Relations</font></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.0%;">
  <p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Central media line&nbsp;:</font></b><font size="2" style="font-size:10.0pt;">
  +41 61 324 2200</font></p>
  </td>
  <td width="52%" valign="top" style="padding:0in 0in 0in 0in;width:52.0%;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.0%;">
  <p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Eric Althoff</font></b></p>
  </td>
  <td width="52%" valign="top" style="padding:0in 0in 0in 0in;width:52.0%;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Heather Bochner</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.0%;">
  <p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Novartis Global Media Relations</font></p>
  </td>
  <td width="52%" valign="top" style="padding:0in 0in 0in 0in;width:52.0%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Novartis Oncology</font></p>
  </td>
 </tr>
 <tr>
  <td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.0%;">
  <p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">+41 61 324 7999 (direct)</font></p>
  </td>
  <td width="52%" valign="top" style="padding:0in 0in 0in 0in;width:52.0%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">+1 862 778 5092</font></p>
  </td>
 </tr>
 <tr>
  <td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.0%;">
  <p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">+41 79 593 4202 (mobile)</font></p>
  </td>
  <td width="52%" valign="top" style="padding:0in 0in 0in 0in;width:52.0%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">heather.bochner@novartis.com</font></p>
  </td>
 </tr>
 <tr>
  <td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.0%;">
  <p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">eric.althoff@novartis.com</font></p>
  </td>
  <td width="52%" valign="top" style="padding:0in 0in 0in 0in;width:52.0%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
 </tr>
</table>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">e-mail: media.relations@novartis.com</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">For
Novartis multimedia content, please visit www.thenewsmarket.com/Novartis. <br>
For questions about the site or required registration, please contact:
journalisthelp@thenewsmarket.com.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Novartis Investor Relations</font></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<table border="1" cellspacing="0" cellpadding="0" width="100%" style="border:none;border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="225" valign="top" style="border:none;padding:0in 0in 0in 0in;width:168.75pt;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Central phone:</font></b></p>
  </td>
  <td width="135" valign="top" style="border:none;padding:0in 0in 0in 0in;width:101.25pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">+41 61 324 7944</font></p>
  </td>
  <td width="202" valign="top" style="border:none;padding:0in 0in 0in 0in;width:2.1in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="158" valign="top" style="border:none;padding:0in 0in 0in 0in;width:1.65in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="225" valign="top" style="border:none;padding:0in 0in 0in 0in;width:168.75pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Susanne Schaffert</font></p>
  </td>
  <td width="135" valign="top" style="border:none;padding:0in 0in 0in 0in;width:101.25pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">+41 61 324 3769</font></p>
  </td>
  <td width="202" valign="top" style="border:none;padding:0in 0in 0in 0in;width:2.1in;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">North America:</font></b></p>
  </td>
  <td width="158" valign="top" style="border:none;padding:0in 0in 0in 0in;width:1.65in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="225" valign="top" style="border:none;padding:0in 0in 0in 0in;width:168.75pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Pierre-Michel Bringer</font></p>
  </td>
  <td width="135" valign="top" style="border:none;padding:0in 0in 0in 0in;width:101.25pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">+41 61 324 1065</font></p>
  </td>
  <td width="202" valign="top" style="border:none;padding:0in 0in 0in 0in;width:2.1in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Richard Jarvis</font></p>
  </td>
  <td width="158" valign="top" style="border:none;padding:0in 0in 0in 0in;width:1.65in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">+1 212 830 2433</font></p>
  </td>
 </tr>
 <tr>
  <td width="225" valign="top" style="border:none;padding:0in 0in 0in 0in;width:168.75pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Thomas Hungerbuehler</font></p>
  </td>
  <td width="135" valign="top" style="border:none;padding:0in 0in 0in 0in;width:101.25pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">+41 61 324 8425</font></p>
  </td>
  <td width="202" valign="top" style="border:none;padding:0in 0in 0in 0in;width:2.1in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Jill Pozarek</font></p>
  </td>
  <td width="158" valign="top" style="border:none;padding:0in 0in 0in 0in;width:1.65in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">+1 212 830 2445</font></p>
  </td>
 </tr>
 <tr>
  <td width="225" valign="top" style="border:none;padding:0in 0in 0in 0in;width:168.75pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Isabella Zinck</font></p>
  </td>
  <td width="135" valign="top" style="border:none;padding:0in 0in 0in 0in;width:101.25pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">+41 61 324 7188</font></p>
  </td>
  <td width="202" valign="top" style="border:none;padding:0in 0in 0in 0in;width:2.1in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Edwin Valeriano</font></p>
  </td>
  <td width="158" valign="top" style="border:none;padding:0in 0in 0in 0in;width:1.65in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">+1 212 830 2456</font></p>
  </td>
 </tr>
 <tr>
  <td width="225" valign="top" style="border:none;padding:0in 0in 0in 0in;width:168.75pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="135" valign="top" style="border:none;padding:0in 0in 0in 0in;width:101.25pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="202" valign="top" style="border:none;padding:0in 0in 0in 0in;width:2.1in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="158" valign="top" style="border:none;padding:0in 0in 0in 0in;width:1.65in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="360" colspan="2" valign="top" style="border:none;padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">e-mail:
  investor.relations@novartis.com</font></p>
  </td>
  <td width="360" colspan="2" valign="top" style="border:none;padding:0in 0in 0in 0in;width:3.75in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">e-mail:
  investor.relations@novartis.com</font></p>
  </td>
 </tr>
</table>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\105953\10-20551-2\task4342131\20551-2-ba.htm',USER='105953',CD='Nov  4 08:15 2010' -->


<br clear="all" style="page-break-before:always;">


<div>

<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SIGNATURES</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
  <p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="50%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Novartis
  AG</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
  <p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="50%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
  <p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="50%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
  <p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date:&nbsp; November&nbsp;3,
  2010</font></p>
  </td>
  <td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.16%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>
  </td>
  <td width="45%" colspan="2" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:45.84%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/
  MALCOLM B. CHEETHAM</font></p>
  </td>
 </tr>
 <tr>
  <td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
  <p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="50%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
  <p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="6%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:6.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>
  </td>
  <td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.34%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Malcolm
  B. Cheetham</font></p>
  </td>
 </tr>
 <tr>
  <td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
  <p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="6%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:6.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>
  </td>
  <td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.34%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Head
  Group Financial</font></p>
  </td>
 </tr>
 <tr>
  <td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
  <p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="6%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:6.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.34%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Reporting
  and Accounting</font></p>
  </td>
 </tr>
 <tr height="0">
  <td width="374" style="border:none;"></td>
  <td width="31" style="border:none;"></td>
  <td width="19" style="border:none;"></td>
  <td width="324" style="border:none;"></td>
 </tr>
</table>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\105953\10-20551-2\task4342131\20551-2-ba.htm',USER='105953',CD='Nov  4 08:15 2010' -->


</body>

</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g205512bai001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g205512bai001.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"``I`,`#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#WZBBN;O=>
METOQ1!83D/;70^0XYC-1.HH*\C6E2E5;4=[7-AM5L%O/LC7<0N,X\LMS^57*
M\OU*Q4_&*T&"?,3S.E>H5T5::@HVZHXJ%651R36SL%%%%9'0%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`([K&C.YPJC)/H*\ULFE\4^.O
MM/6VMFR/3`_QKT'4P6TJ["@DF%\`?0UQ7PR*+#?HV!,'7@]<8KBQ/OU84WMO
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MQ-+A+?%G47MA^[2/,V/4UK_$#26U+PX\T(_TBT83(1UX[5?)351)[/\`"YDJ
MM65"4D]8M_.QJ>(=:.AZ>ERL/GN\BQI$#RQ/I6G;M(\"-,FR0C++Z>U</HU^
M/&.IZ9,?^/>P@$DH[&4\8_#&:Z_5[]-,TFYO).D2$CW/:LYPY;0ZFU*KSWJ7
M]WI^K,VR\4VUYXKO-$3`:W0$-G[S=Q6^<XXZUX[,;K1I=+UUK&XAG67_`$R5
MUPK!CZ]^*]?AE2>&.6,Y1U#*?8U5>DH6<=B,+7E4YE+=?D]CDD\8WDVHZI8P
M:4TLNG<RX<#</:MKP_K]OXATH7T"-'@E7C;JI':O/X;O4K+Q?XPETVS2Y('[
MP,^"HQU`[UV'@,:?_P`(S$;&3S"Q+3$C!#GJ"*NM3C&%TNWY&6'K3G4Y6^_X
M/2WZD.H^*-4TNQN+^XT=OLL;<,'&2OKBK.G:[JE^;.4Z28[6X()D+@[0?:F?
M$#_D2[__`'1_.M'PS_R+.G?]<%_E4/E]GS<O6QJN?V_)S.UK].Y#XHUYO#FF
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M9RV]KRLDAD)/7FFZ]H;:[#%`UT\,*.'95_CQV/M6Q15>TES<U]2?90Y/9VT,
M[5]'AUG1I--N"1&Z@%AU&.])HFER:1IJV37;W"QC"._4#TK2HI<[Y>7H/V<>
M;GMJ<[I7A;^R]=O=5%V\DEZ?WR,.#1:>$XM-UF6_TZ[EMXYSNEMA]PGUKHJ*
MKVL^Y"H4U;3;4RO$&C#7M+>P:=H8Y/OE>IJ;2-/;2].BLVG,RQ`*C-UQ5^BI
MYWR\O0OV<>?GZF-XET!?$>GBRDN'ACW!B4ZDBM"PMGL[**WDE,IC4*'/4@59
MHHYWR\O0%3BI.?5G-2^%[EFNXH]6G2SNF+/'W&>H'M6[86,&FV,-G;+MBB4*
0HJQ13E4E)68H4H0=TC__V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
